Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 11, 2024

Utility of the Antibody–Drug Conjugate Sacituzumab Govitecan to Enable Sequential TOP1/PARP Inhibitor Cancer Therapy in Patients With Breast Cancer

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients
Clin. Cancer Res 2024 May 06;[EPub Ahead of Print], A Bardia, S Sun, N Thimmiah, JT Coates, B Wu, RO Abelman, L Spring, B Moy, P Ryan, MN Melkonyan, A Partridge, D Juric, J Peppercorn, H Parsons, SA Wander, V Attaya, B Lormil, M Shellock, A Nagayama, V Bossuyt, SJ Isakoff, SM Tolaney, LW Ellisen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading